Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
The peptide-based vaccine induces a t cell-dependent response
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
An upgraded, state-of-the-art integrated app, helps easy discovery of expert surgeons for convenient in-clinic or online consultation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
